Skip to main content

Published locations for Atezolizumab+bevacizumab: A better first-line treatment option for unresectable HCC than lenvatinib

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Atezolizumab+bevacizumab: A better first-line treatment option for unresectable HCC than lenvatinib

User login

  • Reset your password
  • /content/atezolizumabbevacizumab-better-first-line-treatment-option-unresectable-hcc-lenvatinib
  • /fedprac/article/259609/hepatocellular-carcinoma/atezolizumabbevacizumab-better-first-line-treatment